Write to us
enquiry@myfinb.com
Call us
+65 6978 4048 (SG)
+60 19-919 9149 (MY)

Study: AI might prove helpful against asbestos-linked cancer

"A new international genomics research led by the University of Leicester used artificial intelligence (AI) to study an aggressive form of cancer, which could be helpful in improving patient outcomes. ...New research undertaken by the Leicester Mesothelioma Research Programme has now revealed, using AI analysis of DNA-sequenced mesotheliomas, that they evolve along similar or repeated paths between individuals. These paths predict the aggressiveness and possible therapy of this otherwise incurable cancer."

A new international genomics research led by the University of Leicester used artificial intelligence (AI) to study an aggressive form of cancer, which could be helpful in improving patient outcomes.

Mesothelioma is caused by breathing asbestos particles and most commonly occurs in the linings of the lungs or abdomen. Currently, only seven per cent of people survive five years after diagnosis, with a prognosis averaging 12 to 18 months.

New research undertaken by the Leicester Mesothelioma Research Programme has now revealed, using AI analysis of DNA-sequenced mesotheliomas, that they evolve along similar or repeated paths between individuals. These paths predict the aggressiveness and possible therapy of this otherwise incurable cancer.

Professor Dean Fennell, Chair of Thoracic Medical Oncology at the University of Leicester and Director of the Leicester Mesothelioma Research Programme, said: “It has long been appreciated that asbestos causes mesothelioma, however, how this occurs remains a mystery.”

“Using AI to interrogate genomic ‘big data’, this initial work shows us that mesotheliomas follow ordered paths of mutations during development and that these so-called trajectories predict not only how long a patient may survive, but also how to better treat cancer – something Leicester aims to lead on internationally through clinical trial initiatives.”

While the use of asbestos is now outlawed – and stringent regulations in place on its removal – each year around 25 people are diagnosed with mesothelioma in Leicestershire and 190 are diagnosed in the East Midlands. Cases of mesothelioma in the UK have increased by 61 per cent since the early 1990s.

Until very recently, chemotherapy was the only licenced choice for patients with mesothelioma. However, treatment options start to become limited once people stop responding to their treatment.

Professor Fennell in collaboration with the University of Southampton recently made a major breakthrough in treating the disease by demonstrating that the use of an immunotherapy drug called nivolumab increased survival and stabilised the disease for patients. This was the first-ever trial to demonstrate improved survival in patients with relapsed mesothelioma.

Source: Asian News International

Share:

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on telegram
Telegram
Share on whatsapp
WhatsApp
Share on email
Email

AI Blog – Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. 

Browse more

Related Posts

AI Blog

AI in courts will aid decision-making for legal fraternity, litigants

“With impressive advances having been made in artificial intelligence (AI), the Indian judiciary has been early to adopt it too. Soon, AI will be tailored for the justice delivery system, playing a vital role in improving administrative efficiency in courts, and aiding in decision-making processes for lawyers, judges and litigants. But how could robots decide questions of law and extract the accurate position of law from a mass of precedents?”

Read More »
AI Blog

Nuritas and Sumitomo partner up in AI-powered pact to discover food-derived peptides

“Nuritas is to provide Sumitomo Chemical with its
Artificial Intelligence (AI)-powered peptide discovery services in a multi-year partnership that addresses food growth to satisfy a growing global population.

Announced last week, the deal will see Nuritas deploy its technology platform, which also uses DNA analysis to predict, unlock, and validate efficacious plant-based peptides.”

Read More »